Interleukin 2 therapy in cancer: identification of responders

Interleukin 2 therapy in cancer: identification of responders

C-reactive protein (CRP) levels in serum were measured in fifteen patients with metastatic colorectal carcinoma, prior to and during treatment with a continuous intravenous infusion of rIL.2. Patients were subsequently classified as responders or non-responders to this therapy. Baseline serum CRP le...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 1992-12, Vol.66 (6), p.1185-1187
Hauptverfasser: BROOM, J, HEYS, SD, WHITING, PH, PARK, KGM, STRACHAN, A, ROTHNIE, FRANKS, CR, EREMIN, O
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antineoplastic agents
Biological and medical sciences
Biomarkers - blood
C-Reactive Protein - analysis
Colorectal Neoplasms - blood
Colorectal Neoplasms - therapy
Female
Humans
Immunotherapy
Infusions, Intravenous
Interleukin-2 - therapeutic use
Life Sciences & Biomedicine
Male
Medical sciences
Middle Aged
Oncology
Pharmacology. Drug treatments
Prognosis
Recombinant Proteins - therapeutic use
Science & Technology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:C-reactive protein (CRP) levels in serum were measured in fifteen patients with metastatic colorectal carcinoma, prior to and during treatment with a continuous intravenous infusion of rIL.2. Patients were subsequently classified as responders or non-responders to this therapy. Baseline serum CRP levels, prior to treatment, were significantly lower in the responders (range
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1992.433